Compare AbbVie Inc (ABBV) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Upstart Holdings Inc — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while Upstart Holdings Inc trades at $31.49 (market cap $3.16B). The key difference: AbbVie Inc is far larger — about 142.4× Upstart Holdings Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | UPST | |
|---|---|---|
Market Cap | $449.91B | $3.16B |
Sector | Health | Financials |
52-Week High | $261.07 | $84.13 |
52-Week Low | $184.85 | $24.22 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Upstart trades at $33.06, down 4.95% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported $1.02B revenue in 2025 with net income of $53.60M, marking a return to profitability after previous losses. Recent news highlights AI lending growth and a $600M funding deal with Neuberger (Business Wire, June 24, 2026).
Outlook is cautiously optimistic with a consensus price target of $43.00 (45% buy ratings), but risks include volatile cash flows, high debt-to-asset ratio of 61.48%, and execution challenges in expanding auto/home lending products. The stock offers upside if AI-driven originations sustain growth, yet remains sensitive to funding and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
